Morphotek To Present Poster On CA125 Suppression Of Humoral Immune Responses Of Antibodies At The Upcoming ASCO-SITC Clinical Immuno-oncology Symposium
EXTON, Pa., Jan. 24, 2018 /PRNewswire/ -- Morphotek(®), Inc., a subsidiary of Eisai Inc., announced today that it will present the following poster at the ASCO-SITC Clinical Immuno-oncology Symposium being held at the Marriott Marquis in San Francisco, CA from January 25-27, 2018:
Title:
The Tumor-shed Antigen CA125
Suppresses Humoral Immune Responses
of IgG1, IgG3 and IgM-type
Antibodies
Poster Session A:
Abstract #: 15
Poster Board: C4
Presentation Time:
Date: Thursday,
January 25, 2018
Time: 11:30 a.m. to
1:30 p.m. and 5:30 p.m. to 6:30
p.m. PST
"We are pleased to have this opportunity to present our continued research findings on the immunosuppressive effects by tumor-produced CA125 on antibody-mediated humoral immunity," said Nicholas Nicolaides, President and CEO of Morphotek. "These findings have potential implications for prescreening development-stage monoclonal antibodies that may be negatively affected by CA125, as well as for identifying patients who may be at risk for developing certain types of cancer, including ovarian carcinoma via host humoral immune-mediated suppression."
About Morphotek
Morphotek(®), Inc., a subsidiary of Eisai Inc., is a clinical-stage biotechnology company focused on developing novel classes of biological-based products to treat cancer, inflammatory and infectious diseases. Our mission is to develop novel targeted therapies that attack underlying disease pathways, and in oncology indications, that can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies. Our diverse pipeline includes clinical-stage biological products to lead targets folate receptor alpha, mesothelin and endosialin, as well as antibody-drug conjugates and bispecific antibodies to undisclosed targets in preclinical development. Our mission is supported by proprietary cutting-edge technologies in antibody engineering, manufacturing and screening optimization platforms, along with our expertise in developing diagnostics to support patient selection and therapeutic strategy. For more information, please visit www.morphotek.com.
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
Morphotek Contacts:
Investor Inquiries: Media Inquiries:
Rod Dausch Diana Martens
610-423-6111 610-423-6085
dausch@morphotek.com dmartens@morphotek.com
View original content with multimedia:http://www.prnewswire.com/news-releases/morphotek-to-present-poster-on-ca125-suppression-of-humoral-immune-responses-of-antibodies-at-the-upcoming-asco-sitc-clinical-immuno-oncology-symposium-300583328.html
SOURCE Morphotek, Inc.
